Decreased incidence of shoulder arthroplasty in patients prescribed anti-resorptive therapy for osteoporosis
Authors' conclusion
OP medications in patients with shoulder OA were associated with a reduced incidence of TSA. No differences were observed between denosumab and bisphosphonates.
Study context
- Population
- Patients with osteoporosis (OP) diagnosed with primary shoulder osteoarthritis (OA), TriNetX database
- Participants
- 4,163 / 4,163 / 844 / 844
- Exposure
- Antiresorptive therapy vs untreated OP controls
- Antiresorptive therapyn = 4,163
- Untreated controlsn = 4,163reference
- Denosumabn = 844
- Bisphosphonatesn = 844reference
- Outcome
- Incidence of total shoulder arthroplasty (TSA), in addition to TSA-free survival
- Follow-up
- 5 years
Methodological detailspropensity-score matched (1:1), TriNetX database
- Propensity-score matched (1:1)
- TriNetX database
Main finding
TSA incidence
Hazard ratio
0.69
95% CI 0.52–0.93
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| TSA incidence, denosumabvs bisphosphonates (sub-analysis) · 5 yearsKaplan-Meier analysis | 1.25 (0.58–2.67) | |
| 0.20.5125Hazard ratio (log scale) |
| Outcome | Denosumab | Bisphosphonates | P value |
|---|---|---|---|
| TSA incidence, denosumab vs bisphosphonates (sub-analysis) · 5 years | 1.8% | 1.4% | P = 0.561 |
Original publication
Decreased incidence of shoulder arthroplasty in patients prescribed anti-resorptive therapy for osteoporosis. Osteoporos Int. Published 29 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →